Overview
- 24 public-safe observations are available for this inspection.
- 6 structured CFR citations are represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
26 Apr 2017
21 CFR 211.113(a)
Procedures for non-sterile drug products
Cited by Stephen D Brown, Shatina R Alridge
26 Apr 2017
21 CFR 211.166(a)
Lack of written stability program
Cited by Stephen D Brown, Shatina R Alridge
26 Apr 2017
21 CFR 211.180(e)(1)
Review of representative number of batches
Cited by Stephen D Brown, Shatina R Alridge
26 Apr 2017
21 CFR 211.180(e)(1)
Review of representative number of batches
Cited by Stephen D Brown, Shatina R Alridge
26 Apr 2017
21 CFR 211.192
Investigations of discrepancies, failures
Cited by Stephen D Brown, Shatina R Alridge
Inspected site
BPBrio Pharmaceuticals IncHouston, United States
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.113(a) | Cited across public-safe Form 483 observations | 4x |
| 21 CFR 211.166(a) | Cited across public-safe Form 483 observations | 4x |
| 21 CFR 211.180(e)(1) | Cited across public-safe Form 483 observations | 4x |
| 21 CFR 211.192 | Cited across public-safe Form 483 observations | 4x |
| 21 CFR 211.198(a) | Cited across public-safe Form 483 observations | 4x |
| 21 CFR 314.80(b) | Cited across public-safe Form 483 observations | 4x |
Source document
PDF
PDF available
Form 483 source document
The source document is available to authorized Atlas users.
Full 483 report
Get the verbatim text of all 24 observations
The source PDF, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere